Immunology Catalyst, GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Immunology Catalyst, GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
Trends Mol Med. 2017 Feb;23(2):165-180. doi: 10.1016/j.molmed.2016.12.007. Epub 2017 Jan 18.
The inflammasome is a cytoplasmic protein complex that processes interleukins (IL)-1β and IL-18, and drives a form of cell death known as pyroptosis. Oligomerization of this complex is actually the second step of activation, and a priming step must occur first. This involves transcriptional upregulation of pro-IL-1β, inflammasome sensor NLRP3, or the non-canonical inflammasome sensor caspase-11. An additional aspect of priming is the post-translational modification of particular inflammasome constituents. Priming is typically accomplished in vitro using a microbial Toll-like receptor (TLR) ligand. However, it is now clear that inflammasomes are activated during the progression of sterile inflammatory diseases such as atherosclerosis, metabolic disease, and neuroinflammatory disorders. Therefore, it is time to consider the endogenous factors and mechanisms that may prime the inflammasome in these conditions.
炎症小体是一种细胞质蛋白复合物,可对白细胞介素 (IL)-1β 和 IL-18 进行加工,并引发一种称为细胞焦亡的细胞死亡形式。该复合物的寡聚化实际上是激活的第二步,首先必须发生一个引发步骤。这涉及到前体 IL-1β、炎症小体传感器 NLRP3 或非经典炎症小体传感器 caspase-11 的转录上调。引发的另一个方面是特定炎症小体成分的翻译后修饰。引发通常在体外使用微生物 Toll 样受体 (TLR) 配体来完成。然而,现在很清楚,炎症小体在动脉粥样硬化、代谢疾病和神经炎症性疾病等无菌性炎症性疾病的进展过程中被激活。因此,现在是时候考虑在这些情况下可能引发炎症小体的内源性因素和机制了。